Stephens Inc. AR Buys New Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

Stephens Inc. AR purchased a new stake in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 32,447 shares of the technology company's stock, valued at approximately $905,000. Stephens Inc. AR owned 0.16% of Simulations Plus as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. First Horizon Advisors Inc. raised its holdings in shares of Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company's stock worth $26,000 after buying an additional 370 shares during the period. nVerses Capital LLC lifted its position in shares of Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company's stock worth $38,000 after purchasing an additional 1,100 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Simulations Plus during the third quarter valued at $59,000. US Bancorp DE grew its holdings in shares of Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company's stock worth $159,000 after purchasing an additional 1,343 shares during the last quarter. Finally, Pitcairn Co. increased its stake in Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company's stock worth $211,000 after buying an additional 549 shares during the period. 78.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SLP has been the topic of a number of research analyst reports. BTIG Research dropped their target price on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, October 24th. KeyCorp raised their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. StockNews.com cut Simulations Plus from a "hold" rating to a "sell" rating in a report on Monday, November 4th. Stephens started coverage on Simulations Plus in a research note on Friday, November 15th. They set an "overweight" rating and a $39.00 price target on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $49.40.

Simulations Plus Stock Down 1.6 %

Shares of NASDAQ SLP traded down $0.59 during mid-day trading on Monday, reaching $36.42. 108,532 shares of the company were exchanged, compared to its average volume of 215,492. Simulations Plus, Inc. has a 1 year low of $24.00 and a 1 year high of $51.22. The firm has a 50-day moving average of $31.50 and a 200 day moving average of $32.19. The stock has a market cap of $731.68 million, a price-to-earnings ratio of 91.05 and a beta of 0.83.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the completion of the sale, the director now directly owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.40% of the stock is owned by insiders.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.